BMY

Bristol-Myers Squibb Co

$64.86

0.95 (1.49%) Today

0.21 (0.32%) After-hours

— up— down

Compare BMY

Market Cap

$130.12B+35.1%

Revenue (TTM)

$49.04B+3.1%

Net Income (TTM)

$9.27B+99.3%

EPS (TTM)

4.54+99.3%

Shares Out

2.04B

P/E Ratio

14.21

Forward P/E

10.35

Dividend

$2.51 (3.96%)

Ex-Dividend Date

Jul 2, 2026

Open

$64.05

Previous Close

$63.70

Day Range

$63.91 – $65.02

52-Week Range

$42.52 – $68.10

Beta

0.17

Volume

8.06M

Avg Volume

11.59M

Analyst Rating

Buy

Exchange

NEW YORK STOCK EXCHANGE, INC.

About BMY

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.